Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis

医学 丙酸倍他米松 钙泊三醇 银屑病 随机对照试验 临床终点 倍他米松 皮肤病科 外科 内科学
作者
Andreas Pinter,Adam Reich,P. Arenberger,Linda Stein Gold,April W. Armstrong,Lars Iversen,Morten Præstegaard,Matthias Augustin
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:37 (11): 2327-2335 被引量:6
标识
DOI:10.1111/jdv.19330
摘要

The fixed dose combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) is a well-established topical treatment option for psoriasis based on strong scientific rationale for the single agents having complementary efficacy and safety. CAL/BDP PAD-cream is an easily spreadable cream based on PAD Technology™, an innovative formulation and drug delivery system.A Phase 3, multicentre, randomized, investigator-blind, active and vehicle-controlled trial enrolling 490 patients with mild to moderate psoriasis according to the Physician Global Assessment (PGA) scale was conducted in three European countries. Products were applied once daily for 8 weeks. The aim of the trial was to evaluate the efficacy and safety of CAL/BDP PAD-cream as well as treatment acceptability compared to CAL/BDP gel and PAD-cream vehicle. Primary endpoint was percentage change in modified Psoriasis Area and Severity Index (mPASI) from baseline to Week 8.The percentage mean change from baseline to Week 8 in mPASI for CAL/BDP PAD-cream (67.5%) was superior compared to PAD-cream vehicle (11.7%; p < 0.0001) and non-inferior to CAL/BDP gel (63.5%). The proportion of patients achieving PGA treatment success (at least two-step improvement to clear or almost clear) after 8 weeks was superior for CAL/BDP PAD-cream (50.7%) compared to PAD-cream vehicle (6.1%, p < 0.0001) and statistically significantly greater than CAL/BDP gel (42.7%, p = 0.0442). Patient-reported psoriasis treatment convenience score (PTCS) for CAL/BDP PAD-cream was rated superior to CAL/BDP gel at Week 8 (p < 0.0001) and the mean change in DLQI from baseline to Week 8 improved statistically significantly more in the CAL/BDP PAD-cream group compared to both PAD-cream vehicle (p < 0.0001) and CAL/BDP gel (p = 0.0110). Safety assessments during the trial demonstrated that CAL/BDP PAD-cream was well-tolerated.CAL/BDP PAD-cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava的应助被WWW采纳,获得10
1秒前
1秒前
Nole的应助被Hao采纳,获得10
2秒前
如风随水的应助被风吹麦浪采纳,获得200
2秒前
2秒前
酷波er的应助被风吹麦浪采纳,获得10
2秒前
2秒前
ye完成签到,获得积分20
3秒前
4秒前
英姑的应助被小周爱学术采纳,获得10
5秒前
5秒前
6秒前
zik发布了新的文献求助10
6秒前
7秒前
虚拟的仰发布了新的文献求助10
7秒前
9秒前
你吴哥发布了新的文献求助10
9秒前
9秒前
卷卷完成签到 ,获得积分10
9秒前
xliiii完成签到,获得积分10
9秒前
moxinyi关注了科研通微信公众号
10秒前
仁兼内圣外王完成签到,获得积分10
10秒前
丰富语蕊的应助被ikouyo采纳,获得20
10秒前
11秒前
11秒前
Su完成签到,获得积分10
11秒前
12秒前
Nole的应助被三元采纳,获得10
12秒前
13秒前
希望天下0贩的0的应助被悦雨采纳,获得10
13秒前
14秒前
你吴哥发布了新的文献求助10
14秒前
你吴哥发布了新的文献求助10
14秒前
14秒前
你吴哥发布了新的文献求助10
14秒前
你吴哥发布了新的文献求助10
14秒前
路冰完成签到,获得积分10
14秒前
qiqi完成签到,获得积分10
15秒前
虚拟的仰完成签到,获得积分10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188563
求助须知:如何正确求助?哪些是违规求助? 9576328
关于积分的说明 21846521
捐赠科研通 7786563
什么是DOI,文献DOI怎么找? 3435354
关于科研通互助平台的介绍 2559627
邀请新用户注册赠送积分活动 2482336